HK1 and squamous cell lung carcinoma: We show that Hexokinase 1 overexpression can rescue the inhibitory effect of pacritinib on glucose consumption, suggesting Hexokinase 1 as a major driver of elevated glucose consumption in squamous cell lung cancer cells and a potential target for additional therapeutic strategies.